GET DAILY SIGNALSPulmonx (LUNG) Climbs +47% in 30 Days on Q3 Recovery
Key Takeaways
- LUNG shares climbed roughly 47% over the trailing 30 days, from about $1.91 to $2.81, with most of the move concentrated in the sessions following the company's third-quarter 2026 earnings release.
- The rally reflects Pulmonx's return to year-over-year revenue growth, its first global growth quarter since current leadership returned to the company.
- Third-quarter revenue rose 6% to $22.8 million, U.S. revenue grew 7%, and the net loss narrowed 40% to $8.4 million, or $0.19 per share.
- Adjusted EBITDA loss shrank nearly 60% to $3.5 million, while gross margin improved to 76%.
- Over the last quarter, LUNG is up roughly 74%, recovering from a late-September pullback before the post-earnings surge.
- For additional detail, explore Pulmonx's Price Targets, Earnings, and Forecast pages.
- Discover how algorithmic strategies are tracking this move on Tickeron's Trending AI Robots page.
Pulmonx (LUNG) Company Snapshot
Pulmonx Corporation is a commercial-stage medical technology company based in Redwood City, California, focused on minimally invasive treatments for severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Its flagship product, the Zephyr Endobronchial Valve, is an implantable bronchoscopic device that redirects airflow away from diseased portions of the lung. The company's integrated platform also includes the Chartis Pulmonary Assessment System, which measures collateral ventilation, and the LungTraX and StratX cloud-based CT analysis tools that help physicians identify patients and target lobes for treatment.
The Zephyr Valve received U.S. Food and Drug Administration Premarket Approval following a breakthrough-device designation, is commercially available in more than 25 countries, and is included in global treatment guidelines. Pulmonx markets primarily to hospitals and interventional pulmonology centers, with the United States as its largest revenue source. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Investors follow the stock closely because it is a focused, single-franchise medtech name whose growth trajectory hinges on procedure adoption, reimbursement, and commercial execution.
Stock Performance: Last 30 Days and the Quarter
Over the last 30 days, LUNG has advanced roughly 47%, rising from a closing price of $1.91 on September 30, 2026, to approximately $2.81 in late October. The move was heavily back-loaded: shares traded in a narrow range between roughly $1.75 and $1.98 for most of the period before surging immediately after the company reported third-quarter results on October 27, 2026.
The broader quarterly picture is similarly positive. Measured from a closing price of about $1.61 on July 30, 2026, the stock has gained roughly 74% over the trailing three-month period. That advance, however, was not linear. After a summer recovery that carried shares toward $2.50 by late August, the stock gave back ground into September and early October before the latest earnings-driven breakout. From what I see, the pattern suggests a classic post-earnings re-rating after a period of consolidation.
Earnings Report as the Main Catalyst
The dominant catalyst was Pulmonx's third-quarter 2026 earnings report, released after the market close on October 27. The company returned to year-over-year revenue growth, reporting worldwide revenue of $22.8 million, up 6% from $21.5 million a year earlier, and topping the roughly $21.9 million consensus estimate. U.S. revenue increased 7% to $14.9 million, and the company added eight new U.S. treating centers during the quarter.
The profitability story reinforced the revenue recovery. Operating expenses fell 18% year over year to $24.9 million, gross margin improved to 76%, and the net loss narrowed 40% to $8.4 million. Adjusted EBITDA loss contracted nearly 60% to $3.5 million. Management reiterated full-year 2026 revenue guidance of $90 million to $92 million and raised its gross-margin outlook to approximately 77%. Trading volume surged to several million shares on October 28 and 29, versus a typical daily average of roughly 100,000 to 200,000 shares, underscoring the strength of the investor response. I’m watching this closely as the volume spike often signals sustained interest.
Quarterly Turnaround Factors at Play
The quarterly advance reflects a broader turnaround narrative rather than a single event. Entering the period, Pulmonx had endured a prolonged stretch of declining year-over-year revenue, and the stock had traded near its lows in the $1.25 to $1.30 range in late July. Two developments began to shift sentiment: a cost-reduction program that delivered steadily narrower losses, and the renewal of the company's China registration certificate, which allowed commercial activity in the region to restart, with distributor shipments expected to resume early next year.
Balance-sheet repositioning also contributed. Earlier in 2026, Pulmonx restructured its credit facility, extending debt maturity to 2031 and securing access to an additional $20 million in undrawn capital subject to revenue milestones. Management has projected a roughly 30% reduction in full-year cash burn. Combined with the rebuilt U.S. sales force beginning to ramp productivity, these factors set the stage for the third-quarter confirmation that growth had returned, triggering the sharp re-rating seen in the final sessions of the period.
Key Items on the Horizon
Looking ahead, the key question is whether Pulmonx can sustain its return to growth. Investors will watch fourth-quarter revenue and full-year 2026 results against the reiterated $90 million to $92 million outlook, as well as the productivity ramp of the rebuilt U.S. sales organization. The resumption of China distributor shipments, expected by early next year, represents a potential incremental catalyst, though management has noted that timing variability is already contemplated in guidance.
Other factors to monitor include gross-margin trajectory, progress toward reduced cash burn, and any updates on the AeriSeal program, whose revenue contribution is not expected to be material until 2028. As a still-unprofitable micro-cap medtech name, Pulmonx also remains sensitive to reimbursement decisions, procedure-volume trends, and broader shifts in risk appetite for small-cap healthcare equities. One thing that stands out is how these operational milestones could influence the next leg of the move.
Integrating AI Tools Into My Process
When analyzing names like LUNG, I often turn to Tickeron’s AI Trend Prediction Engine to cross-check momentum signals against historical patterns. It helps me gauge whether the recent surge aligns with similar setups in the sector without replacing my own fundamental review. This approach keeps the analysis data-driven while leaving room for judgment on execution risks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LUNG in upward trend: price rose above 50-day moving average on October 28, 2026
LUNG moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend. In 32 of 34 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on LUNG as a result. In 68 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for LUNG just turned positive on October 20, 2026. Looking at past instances where LUNG's MACD turned positive, the stock continued to rise in 41 of 51 cases over the following month. The odds of a continued upward trend are 80%.
The 10-day moving average for LUNG crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.
Following a +59.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where LUNG advanced for three days, in 215 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LUNG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
LUNG broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for LUNG entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.468) is normal, around the industry mean (3.870). P/E Ratio (-2.752) is within average values for comparable stocks, (1.382). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (0.932) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. LUNG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LUNG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement